Mayo Clinic Laboratory and pathology research roundup: July 19
Share this:
The research roundup provides an overview of the past week’s research from Mayo Clinic Laboratories consultants, including featured abstracts and a complete list of published studies and reviews.
Featured Abstract
The prognostic role of MYC structural variants identified by NGS and FISH in multiple myeloma.
Structural variants (SV) of the MYC gene region are common in multiple myeloma (MM) and influence disease progression. However, the prognostic significance of different MYC SVs in MM has not been clearly established. Via Clinical Cancer Research
Published to PubMed This Week
- Iga nephropathy presenting as macroscopic hematuria in 2 pediatric patients after receiving the pfizer COVID-19 vaccine.
Kidney International - Analytical sensitivity and specificity of four point of care rapid antigen diagnostic tests for SARS-CoV-2 using real-time quantitative PCR, quantitative droplet digital PCR, and a mass spectrometric antigen assay as comparator methods.
Clinical Chemistry - In vitro activity of rifampin, rifabutin, and rifapentine against enterococci and streptococci from periprosthetic joint infection.
Microbiology Spectrum - Correction to: ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.
Journal of Nuclear Cardiology - Considerations from the college of american pathologists for implementation of an assay for SARS-COV-2 testing after a change in regulatory status.
Journal of Clinical Microbiology - The COVID-te risk assessment model for venous thromboembolism in hospitalized patients with cancer and COVID-19.
Journal of Thrombosis and Haemostasis - Biomarker testing considerations in the evaluation and management of patients with heart failure: Perspectives from the international federation of clinical chemistry and laboratory medicine committee.
Journal of Cardiac Failure - The role and impact of social media in cardio-oncology during the COVID-19 pandemic.
Current Oncology Reports - Pre-diagnosis major life stressors and breast cancer outcomes.
Breast Cancer Research and Treatment - Randomized phase II trial of capecitabine and lapatinib with or without IMC-A12 (Cituxumumab) in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and chemotherapy: NCCTG N0733 (alliance).
Breast Cancer Research and Treatment
